ALK and neuroblastoma: In the 16 ALK-positive patients (including three ALK-positive patients from the dose-escalation cohort and 13 from the dose-expansion cohort), 15 NSCLC patients had ALK rearrangement and one neuroblastoma patient had an oncogenic ALK gene mutation F1174L [19–21].